What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
Search
Facts About IPF
IPF is a debilitating and fatal lung disease.
IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
L'Arte di Respirare IN IPF
Expert Prof. Richeldi discusses the link between Idiopathic Pulmonary Fibrosis (IPF) and Leonardo da Vinci and importance of taking action early.
IPF Video Infographic
Patient explains how IPF affects his life
A patient with moderate IPF explains how the disease affects his every day life. Learn more here.
Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
importance of velcro-like crackles in IPF diagnosis
Dr. Bonella, Rare Lung Disease Specialist, discusses the importance of accurate & early diagnosis inIdiopathic Pulmonary Fibrosis
Facts about the INPULSIS™ trials
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic
Boehringer Ingelheim Launches New Arabic Website to Support Patients Living with Idiopathic Pulmonary Fibrosis in the Region
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Ofev®
Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Idiopathic Pulmonary Fibrosis treatment launched in Egypt
Lung Diseases
Lung Diseases
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
More than 140 healthcare professionals gather at 3rd edition of Interstitial Lung Disease Summit to discuss latest scientific guidelines
The ILD summit discussed the latest treatment guidelines for ILD which vastly impacts quality of life
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio-Metabolism, Respiratory Diseases and Stroke Management
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease Patients Around the World
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Pulmonary Fibrosis Awareness Month 2020
Hear what Peter Fang said about pulmonary fibrosis awareness month, our commitment to advancing care and our engaging new campaign, ‘the most important postcard you will ever write’